Literature DB >> 21855838

Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study).

Leonardo Tamariz1, Sunil Agarwal, Elsayed Z Soliman, Alanna M Chamberlain, Ronald Prineas, Aaron R Folsom, Marietta Ambrose, Alvaro Alonso.   

Abstract

Atrial fibrillation (AF) is one of the most common arrhythmias seen in clinical practice. Current evidence suggests that serum uric acid (SUA) could be a marker of oxidative damage, a factor reported as a part of the mechanisms of AF. The purpose of the present study was to evaluate whether SUA predicted AF in the Atherosclerosis Risk In Communities (ARIC) study. The present analysis included 15,382 AF-free black and white men and women, aged 45 to 64 years, from the ARIC study, a population-based prospective cohort in the United States. SUA was determined using the uricase-peroxidase method at baseline. The primary outcome was the incidence of AF, defined as the occurrence of AF detected using hospital discharge codes, scheduled study electrocardiograms, and/or death certificates during the follow-up period (1987 to 2004). We identified 1,085 cases of incident AF. In Cox proportional hazards models adjusted for age, gender, race, center, education, body mass index, serum glucose, systolic and diastolic blood pressure, low-density lipoprotein cholesterol, alcohol use, prevalent coronary heart disease and heart failure, serum creatinine, diuretics, and P-wave duration on the electrocardiogram (as a measure of left atrial size) at baseline, the hazard ratio of AF associated with a SD increment in SUA was 1.16 (95% confidence interval 1.06 to 1.26). The association of SUA with AF risk differed by race and gender (p for interaction <0.01). In conclusion, elevated SUA is associated with a greater risk of AF, particularly among blacks and women. Additional studies should replicate this association and explore potential mechanisms. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21855838      PMCID: PMC3404126          DOI: 10.1016/j.amjcard.2011.06.043

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  28 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study.

Authors:  F L Brancati; W H Kao; A R Folsom; R L Watson; M Szklo
Journal:  JAMA       Date:  2000-05-03       Impact factor: 56.272

3.  Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation.

Authors:  C A Carnes; M K Chung; T Nakayama; H Nakayama; R S Baliga; S Piao; A Kanderian; S Pavia; R L Hamlin; P M McCarthy; J A Bauer; D R Van Wagoner
Journal:  Circ Res       Date:  2001-09-14       Impact factor: 17.367

4.  Free radicals irreversibly decrease Ca2+ currents in isolated guinea-pig ventricular myocytes.

Authors:  J S Gill; W J McKenna; A J Camm
Journal:  Eur J Pharmacol       Date:  1995-03-16       Impact factor: 4.432

5.  Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy.

Authors:  T P Cappola; D A Kass; G S Nelson; R D Berger; G O Rosas; Z A Kobeissi; E Marbán; J M Hare
Journal:  Circulation       Date:  2001-11-13       Impact factor: 29.690

6.  Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study.

Authors:  Leo K Niskanen; David E Laaksonen; Kristiina Nyyssönen; Georg Alfthan; Hanna-Maaria Lakka; Timo A Lakka; Jukka T Salonen
Journal:  Arch Intern Med       Date:  2004-07-26

7.  Cardiac and pulmonary causes of dyspnoea--validation of a scoring test for clinical-epidemiological use: the Study of Men Born in 1913.

Authors:  H Eriksson; K Caidahl; B Larsson; L O Ohlson; L Welin; L Wilhelmsen; K Svärdsudd
Journal:  Eur Heart J       Date:  1987-09       Impact factor: 29.983

8.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

9.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.

Authors:  E J Benjamin; D Levy; S M Vaziri; R B D'Agostino; A J Belanger; P A Wolf
Journal:  JAMA       Date:  1994-03-16       Impact factor: 56.272

10.  A genome-wide association study of serum uric acid in African Americans.

Authors:  Bashira A Charles; Daniel Shriner; Ayo Doumatey; Guanjie Chen; Jie Zhou; Hanxia Huang; Alan Herbert; Norman P Gerry; Michael F Christman; Adebowale Adeyemo; Charles N Rotimi
Journal:  BMC Med Genomics       Date:  2011-02-04       Impact factor: 3.063

View more
  33 in total

1.  Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring.

Authors:  A Mantovani; R Rigolon; A Civettini; B Bolzan; G Morani; S Bonapace; C Dugo; G Zoppini; E Bonora; G Targher
Journal:  J Endocrinol Invest       Date:  2017-07-15       Impact factor: 4.256

2.  Temporal relationship between uric acid concentration and risk of diabetes in a community-based study population.

Authors:  Stephen P Juraschek; Mara McAdams-Demarco; Edgar R Miller; Allan C Gelber; Janet W Maynard; James S Pankow; Hunter Young; Josef Coresh; Elizabeth Selvin
Journal:  Am J Epidemiol       Date:  2014-01-12       Impact factor: 4.897

3.  Xanthine oxidase inhibitors in heart failure: where do we go from here?

Authors:  Leonardo Tamariz; Joshua M Hare
Journal:  Circulation       Date:  2015-04-14       Impact factor: 29.690

Review 4.  Antioxidant therapies for the management of atrial fibrillation.

Authors:  Tong Liu; Panagiotis Korantzopoulos; Guangping Li
Journal:  Cardiovasc Diagn Ther       Date:  2012-12

Review 5.  Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project.

Authors:  Alessandro Maloberti; C Giannattasio; M Bombelli; G Desideri; A F G Cicero; M L Muiesan; E A Rosei; M Salvetti; A Ungar; G Rivasi; R Pontremoli; F Viazzi; R Facchetti; C Ferri; B Bernardino; F Galletti; L D'Elia; P Palatini; E Casiglia; V Tikhonoff; C M Barbagallo; P Verdecchia; S Masi; F Mallamaci; M Cirillo; M Rattazzi; P Pauletto; P Cirillo; L Gesualdo; A Mazza; M Volpe; G Tocci; G Iaccarino; P Nazzaro; L Lippa; G Parati; R Dell'Oro; F Quarti-Trevano; G Grassi; A Virdis; C Borghi
Journal:  High Blood Press Cardiovasc Prev       Date:  2020-03-10

Review 6.  Hyperuricemia and Risk of Atrial Fibrillation.

Authors:  Yuansheng Liu
Journal:  J Atr Fibrillation       Date:  2014-02-28

7.  Impact of gout on the risk of atrial fibrillation.

Authors:  Chang-Fu Kuo; Matthew J Grainge; Christian Mallen; Weiya Zhang; Michael Doherty
Journal:  Rheumatology (Oxford)       Date:  2015-12-17       Impact factor: 7.580

8.  Hyperuricemia as a Marker of Reduced Left Ventricular Ejection Fraction in Patients with Atrial Fibrillation: Results of the POL-AF Registry Study.

Authors:  Marcin Wełnicki; Iwona Gorczyca; Wiktor Wójcik; Olga Jelonek; Małgorzata Maciorowska; Beata Uziębło-Życzkowska; Maciej Wójcik; Robert Błaszczyk; Renata Rajtar-Salwa; Tomasz Tokarek; Jacek Bil; Michał Wojewódzki; Anna Szpotowicz; Małgorzata Krzciuk; Monika Gawałko; Agnieszka Kapłon-Cieślicka; Anna Tomaszuk-Kazberuk; Anna Szyszkowska; Janusz Bednarski; Elwira Bakuła-Ostalska; Beata Wożakowska-Kapłon; Artur Mamcarz
Journal:  J Clin Med       Date:  2021-04-22       Impact factor: 4.241

Review 9.  Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins.

Authors:  Ana Catarina Pinho-Gomes; Svetlana Reilly; Ralf P Brandes; Barbara Casadei
Journal:  Antioxid Redox Signal       Date:  2013-10-19       Impact factor: 8.401

10.  Metabolomic Profiling in Relation to New-Onset Atrial Fibrillation (from the Framingham Heart Study).

Authors:  Darae Ko; Eric M Riles; Ernaldo G Marcos; Jared W Magnani; Steven A Lubitz; Honghuang Lin; Michelle T Long; Renate B Schnabel; David D McManus; Patrick T Ellinor; S Vasan Ramachandran; Thomas J Wang; Robert E Gerszten; Emelia J Benjamin; Xiaoyan Yin; Michiel Rienstra
Journal:  Am J Cardiol       Date:  2016-08-24       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.